Journal of the Neurological Sciences
Volume 264, Issue 1 , Pages 77-86 , 15 January 2008

Non-pathogenic protein aggregates in skeletal muscle in MLF1 transgenic mice

  • Zhi-Fang Li

      Affiliations

    • Burnham Institute for Medical Research, 10901 N. Torrey Pines Road. La Jolla, CA 92037, United States
    • These authors contributed equally to this work.
    • ,
  • Xiaohua Wu

      Affiliations

    • Department of Pathology, University of California, San Diego, La Jolla, CA 92093, United States
    • McColl-Lockwood Laboratory for muscular Dystrophy Research, Cannon Research Center, Carolinas Medical Center, Charlotte, NC 28203, United States
    • These authors contributed equally to this work.
    • ,
  • Yun Jiang

      Affiliations

    • Department of Pathology, University of California, San Diego, La Jolla, CA 92093, United States
    • ,
  • Jianxiang Liu

      Affiliations

    • Abgent Inc., San Diego, CA 92121, United States
    • ,
  • Chun Wu

      Affiliations

    • Abgent Inc., San Diego, CA 92121, United States
    • ,
  • Masaki Inagaki

      Affiliations

    • Division of Biochemistry, Aichi Cancer Center Research Institute, Nagoya, Japan
    • ,
  • Ichiro Izawa

      Affiliations

    • Division of Biochemistry, Aichi Cancer Center Research Institute, Nagoya, Japan
    • ,
  • Andrew P. Mizisin

      Affiliations

    • Department of Pathology, University of California, San Diego, La Jolla, CA 92093, United States
    • ,
  • Eva Engvall

      Affiliations

    • Burnham Institute for Medical Research, 10901 N. Torrey Pines Road. La Jolla, CA 92037, United States
    • ,
  • G. Diane Shelton

      Affiliations

    • Department of Pathology, University of California, San Diego, La Jolla, CA 92093, United States
    • Corresponding Author InformationCorresponding author. Department of Pathology 0709, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0709, United States. Tel.: +1 858 534 1537; fax: +1 858 534 0391.

Received 4 May 2007 ,Revised 25 July 2007 ,Accepted 26 July 2007.

References 

  1. Goebel H, Fardeau M. 121st ENMC International Workshop on Desmin and Protein Aggregate Myopathies. 7–9 November 2003, Naarden, The Netherlands. Neuromuscul disord. 2004;14:767–773
  2. Goebel HH, Mueller HD. Protein aggregate myopathies. Semin Pediatr Neurol. 2006;13:98–103
  3. Goebel HH, Warlo I. Gene-related protein surplus myopathies. Mol Genet Metab. 2000;71:267–275
  4. Askanas V, Engel WK. Inclusion-body myositis and myopathies: different etiologies, possibly similar pathogenic mechanisms. Curr Opin Neurol. 2002;15:525–531
  5. Davies JE, Berger Z, Rubinsztein DC. Oculopharyngeal muscular dystrophy: potential therapies for an aggregate-associated disorder. Int J Biochem Cell Biol. 2006;38:1457–1462
  6. Jin LW, Hearn MG, Ogburn CE, Dang N, Nochlin D, Ladiges WC, et al. Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis. Am J Pathol. 1998;153:1679–1686
  7. Sugarman MC, Yamasaki TR, Oddo S, Echegoyen JC, Murphy MP, Golde TE, et al. Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proc Natl Acad Sci U S A. 2002;99:6334–6339
  8. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885–890
  9. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839–840
  10. Cooper JK, Schilling G, Peters MF, Herring WJ, Sharp AH, Kaminsky Z, et al. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum Mol Genet. 1998;7:783–790
  11. Slow EJ, Graham RK, Hayden MR. To be or not to be toxic: aggregations in Huntington and Alzheimer disease. Trends Genet. 2006;22:408–411
  12. Yoneda-Kato N, Look AT, Kirstein MN, Valentine MB, Raimondi SC, Cohen KJ, et al. The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM–MLF1. Oncogene. 1996;12:265–275
  13. Lim R, Winteringham LN, Williams JH, McCulloch RK, Ingley E, Tiao JY, et al. MADM, a novel adaptor protein that mediates phosphorylation of the 14-3-3 binding site of myeloid leukemia factor 1. J Biol Chem. 2002;277:40997–41008
  14. Hanissian SH, Akbar U, Teng B, Janjetovic Z, Hoffmann A, Hitzler JK, et al. cDNA cloning and characterization of a novel gene encoding the MLF1-interacting protein MLF1IP. Oncogene. 2004;23:3700–3707
  15. Winteringham LN, Kobelke S, Williams JH, Ingley E, Klinken SP. Myeloid Leukemia Factor 1 inhibits erythropoietin-induced differentiation, cell cycle exit and p27Kip1 accumulation. Oncogene. 2004;23:5105–5109
  16. Yoneda-Kato N, Tomoda K, Umehara M, Arata Y, Kato JY. Myeloid leukemia factor 1 regulates p53 by suppressing COP1 via COP9 signalosome subunit 3. EMBO J. 2005;24:1739–1749
  17. Kazemi-Esfarjani P, Benzer S. Genetic suppression of polyglutamine toxicity in Drosophila. Science. 2000;287:1837–1840
  18. Kazemi-Esfarjani P, Benzer S. Suppression of polyglutamine toxicity by a Drosophila homolog of myeloid leukemia factor 1. Hum Mol Genet. 2002;11:2657–2672
  19. Fayazi Z, Ghosh S, Marion S, Bao X, Shero M, Kazemi-Esfarjani P. A Drosophila ortholog of the human MRJ modulates polyglutamine toxicity and aggregation. Neurobiol Dis. 2006;24:226–244
  20. Cummings CJ, Sun Y, Opal P, Antalffy B, Mestril R, Orr HT, et al. Overexpression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum Mol Genet. 2001;10:1511–1518
  21. Vacher C, Garcia-Oroz L, Rubinsztein DC. Overexpression of yeast hsp 104 reduces polyglutamine aggregation and prolongs survival of a transgenic mouse model of Huntington's disease. Hum Mol Genet. 2005;14:3425–3433
  22. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. Chaperone suppression of alpha-synuclein toxicity in a Drosophilia model for Parkinson's disease. Science. 2002;295:865–868
  23. Muchowski PJ, Schafar G, Sittler A, Wanker EE, Hayer-Hartl MK, Hartl FU. Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc Natl Acad Sci U S A. 2000;97:7841–7846
  24. Hennessy F, Nicoll WS, Zimmermann R, Cheetham ME, Blatch GL. Not all J domains are created equal: implications for the specificity of Hsp40–Hsp70 interactions. Protein Sci. 2005;14:1697–1709
  25. Muscat GE, Kedes L. Multiple 5′-flanking regions of the human alpha-skeletal actin gene synergistically modulate muscle-specific expression. Mol Cell Biol. 1987;7:4089–4099
  26. Izawa I, Nishizawa M, Ohtakara K, Ohtsuka K, Inada H, Inagaki M. Identification of Mrj, a DnaJ/Hsp40 family protein, as a keratin 8/18 filament regulatory protein. J Biol Chem. 2000;275:34521–34527
  27. Rafael JA, Nitta Y, Peters J, Davies KE. Testing of SHIRPA, mouse phenotype assessment protocol, on Dmd(mdx) and Dmd(mdx3cv) dystrophin deficient mice. Mamm Genome. 2000;11:725–728
  28. Jaworski DM, Soloway P, Caterina J, Falls WA. Tissue inhibitor of metalloproteinase-2 (TIMP-2) deficient mice display motor deficits. J Neurobiol. 2006;66:82–94
  29. Slow EJ, Graham RK, Osmand AP, Devon RS, Lu G, Deng Y, et al. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc Natl Acad Sci U S A. 2005;102:11402–11407
  30. Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R, et al. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci. 1999;19:2522–2534
  31. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 1997;90:537–548
  32. Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet. 2003;12:1555–1567
  33. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;431:805–810
  34. Selcen D, Ohno K, Engel AG. Myofibrillar myopathy: clinical, morphological and genetic studies in 63 patients. Brain. 2004;127:439–451
  35. Dion P, Shanmugam V, Gaspar C, Messaed C, Meijer I, Toulouse A, et al. Transgenic expression of an expanded (GCG)13 repeat PABPN1 leads to weakness and coordination defects in mice. Neurobiol Dis. 2005;18:528–536
  36. Davies JE, Wang L, Garcia-Oroz L, Cook LJ, Vacher C, O'Donovan DG, et al. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat Med. 2005;11:672–677
  37. Uyama E, Hino H, Araki K, Takeya M, Uchino M, Yamamura K. Animal model of oculopharyngeal muscular dystrophy. Acta Myol. 2005;24:84–88
  38. Davies JE, Zdenek B, Rubinsztein DC. Oculopharyngeal muscular dystrophy: potential therapies for an aggregate-associated disorder. Int J Biochem Cell Biol. 2006;38:1457–1462
  39. Berger Z, Davies JE, Luo S, Pasco MY, Jajoul I, O'Kane CJ, et al. Deleterious and protective properties of an aggregate-prone protein with a polyalanine expansion. Hum Mol Genet. 2006;15:453–465

PII: S0022-510X(07)00521-7

doi: 10.1016/j.jns.2007.07.027

Journal of the Neurological Sciences
Volume 264, Issue 1 , Pages 77-86 , 15 January 2008

Article Tools

* Image Usage & Resolution